製品番号: HY-N2421

Sequoyitol

(別名: 5-O-Methyl-myo-inositol)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Sequoyitol (5-O-Methyl-myo-inositol) is an orally active hypoglycemic agent and antioxidant. Sequoyitol can be isolated from herbaceous plants. Sequoyitol downregulates the expression of NF-κB and TGF-β1, reduces ROS production and malondialdehyde levels, and enhances total antioxidant capacity. Sequoyitol activates the insulin signaling pathway, including the phosphorylation of IR, IRS1 and Akt. Sequoyitol increases serum insulin levels, inhibits hepatic glucose production, and promotes cellular glucose uptake. Sequoyitol antagonizes TNFα-induced inhibition of the insulin signaling pathway, and decreases blood urea nitrogen and serum creatinine levels. Sequoyitol elicits potential peaks in the chemosensors of adult and larval Atrophaneura alcinous, and acts as an oviposition stimulant for female Atrophaneura alcinous. Sequoyitol can be used in research related to type 2 diabetes, insulin resistance, hyperglycemia, impaired glucose tolerance and diabetic nephropathy.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 523-92-2
分子式: C₇H₁₄O₆
分子量:194.18

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Sequoyitol 構造式

CAS 番号: 523-92-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

NF-κB アイソフォーム固有の製品をすべて表示 :

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

体外実験

Sequoyitol (1-10 μmol·L⁻¹; added 1 hour prior to the addition of high-glucose medium) protects rat mesangial cells from high-glucose-induced loss of viability, with the 10 μmol·L⁻¹ dose exerting a stronger protective effect^[1].
Sequoyitol (1-10 μmol·L⁻¹; added 1 hour prior to the addition of high-glucose medium) reduces excessive ROS production induced by high glucose in rat mesangial cells, with the 10 μmol·L⁻¹ dose exerting a more significant inhibitory effect on ROS levels^[1].
Sequoyitol (1-10 μmol·L⁻¹) reduces the level of high glucose-induced lipid peroxidation in rat mesangial cells, as evidenced by decreased MDA levels, with the inhibitory effect being stronger at the dose of 10 μmol·L⁻¹^[1].
Sequoyitol (1-10 μmol·L⁻¹) enhances the cellular antioxidant capacity of rat mesangial cells exposed to high glucose, with the 10 μmol·L⁻¹ dose exerting a more significant enhancing effect^[1].
Sequoyitol (100 μM; 12 h) directly enhances the insulin signaling pathway in HepG2 cells, including the phosphorylation of IRS1 and Akt, and reverses TNF-α-induced insulin resistance^[2].
Sequoyitol (100 μM; 16 h) directly suppresses DB-cAMP-stimulated gluconeogenesis in primary mouse hepatocytes in vitro in an insulin-independent manner, and exerts additive or synergistic effects to inhibit gluconeogenesis when combined with insulin^[2].
Sequoyitol (100 μM; 12 h) directly enhances the insulin signaling pathway in 3T3-L1 adipocytes, including the phosphorylation of IR, IRS1 and Akt, and reverses TNF-α-induced insulin resistance^[2].
Sequoyitol (5-10 mg/mL; 3-6 h) dose-dependently protects INS-1 pancreatic β-cells against STZ (HY-13753)- and H₂O₂-induced damage, and enhances the insulin signaling pathway in these cells^[2].
Sequoyitol (15 mM) induces single-amplitude action potentials in the lateral styloconic sensilla of fifth-instar Atrophaneura alcinous larvae, elicits a small number of small action potentials in the epipharyngeal sensilla, but causes no evoked responses in the medial styloconic sensilla^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

human hepatoblastoma HepG2 cells
Concentration:

100 μM
Incubation Time:

12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result:

Increased insulin-stimulated phosphorylation of IRS1 by 114% and Akt (pSer473) by 54% compared to control.
Increased insulin-stimulated phosphorylation of IR by 46%, IRS1 by 48%, and Akt (pSer473) by 61% in TNF-α-treated cells compared to TNF-α-only control.

Western Blot Analysis^[2]

Cell Line:

3T3-L1 mouse adipocytes
Concentration:

100 μM
Incubation Time:

12 h (pretreatment before 5 min insulin stimulation); 12 h (pretreatment with TNF-α before 5 min insulin stimulation)
Result:

Increased insulin-stimulated phosphorylation of IR by 31% and IRS1 by 73% compared to control.
Increased insulin-stimulated phosphorylation of IR by 53%, IRS1 by 69%, and Akt by 74% in TNF-α-treated cells compared to TNF-α-only control.

体内実験

Sequoyitol (12.5-50.0 mg/kg; p.o.; daily; 6 weeks) ameliorates diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic rats by reducing hyperglycemia, improving renal function, decreasing oxidative stress, and downregulating the expression of pro-fibrotic and pro-inflammatory mediators, with the highest dose producing the most significant effects^[1].
Sequoyitol (0.5 nmol/h; s.c.; continuous; 23 days) improves hyperglycemia, hyperinsulinemia, insulin resistance, and glucose intolerance in ob/ob mice by enhancing insulin signaling, including increasing Akt phosphorylation and reducing IRS1 Ser³⁰⁷ phosphorylation^[2].
Sequoyitol (40 mg/kg; p.o.; twice daily; up to 31 days) improves hyperglycemia and glucose intolerance in ob/ob mice of both sexes by enhancing insulin sensitivity without altering body weight or plasma insulin levels^[2].
Sequoyitol (70-100 mg·kg^-1·day^-1; p.o.; continuous; 31 days) reduces hyperglycemia, improves glucose intolerance, and increases plasma insulin levels in STZ-induced insulin-deficient C57BL/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (male, 6-8 weeks old, 180-220 g, induced by 4-week high-fat diet + intraperitoneal streptozotocin injection)^[1]
Dosage:

12.5 mg/kg; 25.0 mg/kg; 50.0 mg/kg
Administration:

p.o.; daily; 6 weeks
Result:

Significantly decreased fasting blood glucose levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant reductions (# P < 0.05, ## P < 0.01).
Significantly increased plasma insulin levels compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses showing statistically significant elevations (# P < 0.05, ## P < 0.01).
Significantly decreased serum creatinine (SCr) and blood urea nitrogen (BUN) levels compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reduction in SCr (## P < 0.01) and all doses producing statistically significant reductions in BUN (# P < 0.05, ## P < 0.01).
Improved renal histopathology, reducing glomerular hypertrophy, mesangial cell proliferation, and extracellular matrix accumulation compared to the diabetic model group.
Significantly decreased renal collagen IV mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal p22phox and p47phox mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).
Significantly decreased renal malondialdehyde (MDA) levels and increased total antioxidative capacity (T-AOC) compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant changes (## P < 0.01).
Significantly decreased renal NF-κB mRNA and protein expression compared to the diabetic model group, with 50.0 mg/kg dose producing statistically significant reductions (## P < 0.01).
Significantly decreased renal TGF-β1 mRNA and protein expression compared to the diabetic model group, with 25.0 mg/kg and 50.0 mg/kg doses producing statistically significant reductions (## P < 0.01).

Animal Model:

ob/ob (male and female, 8-9 wk old, genetic obesity/insulin resistance model)^[2]
Dosage:

40 mg/kg
Administration:

p.o.; twice daily; up to 31 days
Result:

Did not alter body weight in males or females.
Reduced fasting blood glucose significantly in males (P=0.014) and reduced in females (P=0.08) compared to controls.
Lowered blood glucose levels significantly at multiple time points post-glucose injection during GTT in both sexes.
Maintained plasma insulin levels similar to control groups.
Lowered blood glucose levels significantly at 15, 30, and 60 minutes post-insulin injection during ITT in both males and females.

Animal Model:

C57BL/6 (male, 9 wk old, insulin deficiency model induced by streptozotocin injection)^[2]
Dosage:

70-100 mg·kg^-1·day^-1
Administration:

p.o.
Result:

Did not alter body weight.
Reduced random-fed blood glucose significantly at days 22 and 31 post-treatment, with a 26% reduction at day 31 compared to controls.
Increased plasma insulin levels by 155% compared to controls.
Lowered blood glucose levels significantly at 60 and 120 minutes post-glucose injection during GTT.
Reduced AUC during GTT significantly.

化学情報

CAS 番号 523-92-2
性状 Solid
分子量 194.18
分子式 C₇H₁₄O₆
Color White to off-white
SMILES

CO[C@@H]1[C@H]([C@@H]([C@H](O)[C@H](O)[C@H]1O)O)O
別名

5-O-Methyl-myo-inositol
Structure Classification
- Others
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Insects

Electrophysiological and Morphological Characterization of Contact Chemosensilla in Adults and Larvae of the Butterfly, Atrophaneura alcinous. [Abstract]

2022 Sep 2;13(9):802. PMID: 36135503

溶剤 & 溶解度

体外:

H₂O : 100 mg/mL (514.99 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1499 mL

25.7493 mL

51.4986 mL

5 mM

1.0300 mL

5.1499 mL

10.2997 mL

10 mM

0.5150 mL

2.5749 mL

5.1499 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (514.99 mM); Clear solution; Need ultrasonic

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (320 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Li XW, et al. Sequoyitol ameliorates diabetic nephropathy in diabetic rats induced with a high-fat diet and a low dose of streptozotocin. Can J Physiol Pharmacol. 2014;92(5):405-417. [Content Brief]

[2]. Shen H, et al. Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and β-cells. Am J Physiol Endocrinol Metab. 2012;302(8):E932-E940. [Content Brief]

[3]. Tsuchihara K, et al. Electrophysiological and Morphological Characterization of Contact Chemosensilla in Adults and Larvae of the Butterfly, Atrophaneura alcinous. Insects. 2022 Sep 2;13(9):802. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.1499 mL	25.7493 mL	51.4986 mL	128.7465 mL
	5 mM	1.0300 mL	5.1499 mL	10.2997 mL	25.7493 mL
	10 mM	0.5150 mL	2.5749 mL	5.1499 mL	12.8747 mL
	15 mM	0.3433 mL	1.7166 mL	3.4332 mL	8.5831 mL
	20 mM	0.2575 mL	1.2875 mL	2.5749 mL	6.4373 mL
	25 mM	0.2060 mL	1.0300 mL	2.0599 mL	5.1499 mL
	30 mM	0.1717 mL	0.8583 mL	1.7166 mL	4.2916 mL
	40 mM	0.1287 mL	0.6437 mL	1.2875 mL	3.2187 mL
	50 mM	0.1030 mL	0.5150 mL	1.0300 mL	2.5749 mL
	60 mM	0.0858 mL	0.4292 mL	0.8583 mL	2.1458 mL
	80 mM	0.0644 mL	0.3219 mL	0.6437 mL	1.6093 mL
	100 mM	0.0515 mL	0.2575 mL	0.5150 mL	1.2875 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Sequoyitol

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Sequoyitol

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 Sequoyitol

NF-κB アイソフォーム固有の製品をすべて表示

TGF-β Receptor アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)